Dec 02, 2020 / 04:20PM GMT
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - MD
Okay. Thanks, everyone, for joining us this morning. Very pleased to have NovoCure with us. I mean it's a fascinating story. As far as TAM stories go, NovoCure is probably one of the best TAM stories out there. To tell us more about the company, we have Bill Doyle, Chairman of the company; and their Chief Scientific Officer, Uri Weinberg. Bill and Uri, thank you for joining us this morning.
Questions and Answers:
Vijay Muniyappa Kumar - Evercore ISI Institutional Equities, Research Division - MDMaybe let's start on that theme, Bill. I put on my simplistic device hat, right, and sometimes it gets confusing. Is this a biotech stock? Is this a device stock? It has elements of both. And how would you classify the company? Maybe for some people who are not familiar with the story, give an overview of the technology and what it does.
William F. Doyle - NovoCure Limited - Executive Chairman
Sure. So thanks, Vijay. And thanks for having